Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 6 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7481.99 | 1445 / 1445 | 100% | 72.50 | 183 / 183 |
liver | 100% | 4268.38 | 226 / 226 | 100% | 39.66 | 406 / 406 |
ovary | 100% | 8143.60 | 180 / 180 | 100% | 89.38 | 430 / 430 |
pancreas | 100% | 3523.69 | 328 / 328 | 100% | 63.23 | 178 / 178 |
skin | 100% | 7272.64 | 1809 / 1809 | 100% | 71.65 | 472 / 472 |
uterus | 100% | 8634.76 | 170 / 170 | 100% | 63.54 | 459 / 459 |
lung | 100% | 9181.45 | 578 / 578 | 100% | 65.72 | 1153 / 1155 |
prostate | 100% | 7733.63 | 245 / 245 | 100% | 72.26 | 501 / 502 |
kidney | 100% | 5642.51 | 89 / 89 | 100% | 51.73 | 899 / 901 |
stomach | 100% | 5811.91 | 359 / 359 | 100% | 63.84 | 285 / 286 |
intestine | 100% | 7110.89 | 966 / 966 | 100% | 63.94 | 525 / 527 |
bladder | 100% | 7796.52 | 21 / 21 | 100% | 64.28 | 502 / 504 |
thymus | 100% | 6416.90 | 652 / 653 | 100% | 56.53 | 602 / 605 |
breast | 100% | 8431.26 | 459 / 459 | 99% | 68.73 | 1109 / 1118 |
adrenal gland | 100% | 5136.48 | 258 / 258 | 98% | 32.16 | 225 / 230 |
brain | 98% | 2763.43 | 2584 / 2642 | 100% | 65.56 | 705 / 705 |
adipose | 100% | 8423.59 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 9292.59 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 80.01 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 64.05 | 29 / 29 |
muscle | 100% | 5356.16 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7791.51 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 68.13 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 47.01 | 1 / 1 |
heart | 99% | 3988.16 | 856 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 6645.54 | 922 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0006954 | Biological process | inflammatory response |
GO_0032495 | Biological process | response to muramyl dipeptide |
GO_0014040 | Biological process | positive regulation of Schwann cell differentiation |
GO_0038084 | Biological process | vascular endothelial growth factor signaling pathway |
GO_0010224 | Biological process | response to UV-B |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0033590 | Biological process | response to cobalamin |
GO_0051591 | Biological process | response to cAMP |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_1902895 | Biological process | positive regulation of miRNA transcription |
GO_0034142 | Biological process | toll-like receptor 4 signaling pathway |
GO_0030163 | Biological process | protein catabolic process |
GO_0002357 | Biological process | defense response to tumor cell |
GO_0038161 | Biological process | prolactin signaling pathway |
GO_1904996 | Biological process | positive regulation of leukocyte adhesion to vascular endothelial cell |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0071354 | Biological process | cellular response to interleukin-6 |
GO_1904385 | Biological process | cellular response to angiotensin |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0050862 | Biological process | positive regulation of T cell receptor signaling pathway |
GO_0043200 | Biological process | response to amino acid |
GO_0002931 | Biological process | response to ischemia |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0045087 | Biological process | innate immune response |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_1902894 | Biological process | negative regulation of miRNA transcription |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0071223 | Biological process | cellular response to lipoteichoic acid |
GO_0032757 | Biological process | positive regulation of interleukin-8 production |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0099527 | Biological process | postsynapse to nucleus signaling pathway |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0070431 | Biological process | nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0033554 | Biological process | cellular response to stress |
GO_0009887 | Biological process | animal organ morphogenesis |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0071224 | Biological process | cellular response to peptidoglycan |
GO_0001889 | Biological process | liver development |
GO_0046627 | Biological process | negative regulation of insulin receptor signaling pathway |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_1902004 | Biological process | positive regulation of amyloid-beta formation |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0032570 | Biological process | response to progesterone |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006325 | Biological process | chromatin organization |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0035994 | Biological process | response to muscle stretch |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0034097 | Biological process | response to cytokine |
GO_0035729 | Biological process | cellular response to hepatocyte growth factor stimulus |
GO_0051607 | Biological process | defense response to virus |
GO_0032735 | Biological process | positive regulation of interleukin-12 production |
GO_0006117 | Biological process | acetaldehyde metabolic process |
GO_0032868 | Biological process | response to insulin |
GO_0070498 | Biological process | interleukin-1-mediated signaling pathway |
GO_2000630 | Biological process | positive regulation of miRNA metabolic process |
GO_0070555 | Biological process | response to interleukin-1 |
GO_0006968 | Biological process | cellular defense response |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0033234 | Biological process | negative regulation of protein sumoylation |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0001942 | Biological process | hair follicle development |
GO_2001237 | Biological process | negative regulation of extrinsic apoptotic signaling pathway |
GO_0071316 | Biological process | cellular response to nicotine |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005634 | Cellular component | nucleus |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0035525 | Cellular component | NF-kappaB p50/p65 complex |
GO_0071159 | Cellular component | NF-kappaB complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005829 | Cellular component | cytosol |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0042802 | Molecular function | identical protein binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0001223 | Molecular function | transcription coactivator binding |
GO_0071532 | Molecular function | ankyrin repeat binding |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0140296 | Molecular function | general transcription initiation factor binding |
GO_0000979 | Molecular function | RNA polymerase II core promoter sequence-specific DNA binding |
GO_0042826 | Molecular function | histone deacetylase binding |
GO_0019899 | Molecular function | enzyme binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0042277 | Molecular function | peptide binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0042301 | Molecular function | phosphate ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0019901 | Molecular function | protein kinase binding |
GO_0042805 | Molecular function | actinin binding |
GO_0051059 | Molecular function | NF-kappaB binding |
Gene name | RELA |
Protein name | RELA protein (RELA proto-oncogene, NF-kB subunit) RELA protein RELA proto-oncogene, NF-kB subunit Alternative protein RELA Transcription factor p65 (Nuclear factor NF-kappa-B p65 subunit) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3) |
Synonyms | NFKB3 |
Description | FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells . The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection . . |
Accessions | ENST00000525693.5 ENST00000529389.5 E9PMD5 E9PI38 ENST00000531238.1 ENST00000534558.5 E9PKV4 ENST00000534283.1 ENST00000532879.5 E9PNK5 A0A087X0W8 ENST00000308639.13 [Q04206-4] ENST00000533187.5 L0R6N5 E9PJR1 ENST00000525658.5 E9PJZ9 Q2TAM5 Q96CP1 E9PM47 ENST00000533546.5 E9PQS6 ENST00000526257.1 E9PNV4 ENST00000527874.1 E9PSE4 Q04206 ENST00000532999.5 ENST00000527749.5 E9PKH5 ENST00000612991.4 ENST00000406246.8 [Q04206-1] Q96F54 ENST00000526283.6 E9PRX2 H0YCB4 |